Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for digoxin therapeutic drug assay, effective May 15, 2026. Here's what billing teams need to do.
CMS digoxin therapeutic drug assay coverage policy updates don't get the attention they deserve—and that's exactly how claim denials happen. The Centers for Medicare & Medicaid Services has modified this policy, with an effective date of May 15, 2026. The policy does not list specific CPT, HCPCS, or ICD-10 codes in the available data, but digoxin therapeutic drug assay billing touches cardiology, internal medicine, and nephrology practices that manage patients on long-term digoxin therapy. If your team bills for digoxin monitoring, this change belongs on your radar before May 15.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Digoxin Therapeutic Drug Assay |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Internal Medicine, Nephrology, Primary Care |
| Key Action | Review medical necessity documentation for all digoxin therapeutic drug monitoring claims before May 15, 2026 |
CMS Digoxin Therapeutic Drug Assay Coverage Criteria and Medical Necessity Requirements 2026
Digoxin has one of the narrowest therapeutic windows in all of medicine. Too little and it's ineffective. Too much and it's toxic. That's exactly why therapeutic drug monitoring exists—and why CMS has specific views on when a digoxin assay meets medical necessity.
The full policy detail is not publicly available in the current version of this document. However, based on how CMS structures therapeutic drug assay coverage policies, coverage generally hinges on documented clinical necessity. That means your chart notes need to show why the test was ordered—not just that it was ordered.
CMS evaluates digoxin therapeutic drug assay claims against medical necessity standards that typically require an active digoxin prescription and a clinical indication for monitoring. Routine or reflexive ordering without supporting documentation is the fastest path to a claim denial. Your ordering providers need to document the clinical rationale every time.
Whether prior authorization applies to digoxin therapeutic drug assays under this updated coverage policy depends on your Medicare Administrative Contractor. MAC-level local coverage determinations can layer additional requirements on top of the national policy. Pull your MAC's LCD for therapeutic drug monitoring before May 15 and compare it against what your team currently submits.
The real issue with therapeutic drug monitoring policies is that they look simple on the surface—order the test, bill the code—but CMS scrutinizes frequency and clinical context. If your practice bills high volumes of digoxin assays, especially in long-term care or home health settings, expect closer review under the updated policy.
CMS Digoxin Therapeutic Drug Assay Exclusions and Non-Covered Indications
The available policy data does not include a specific exclusions list for this modification. That said, CMS consistently treats certain patterns as non-covered under therapeutic drug assay billing guidelines.
Monitoring in the absence of an active digoxin prescription is not covered. Neither is testing ordered purely as a preventive screen with no documented clinical indication. If a patient has been off digoxin for months and a provider orders an assay without clinical justification, CMS will not reimburse it—and the documentation burden falls on your billing team to prove coverage applied.
Frequency is the other common exclusion trigger. CMS typically does not cover assays ordered more frequently than clinical guidelines support. If your practice has standing orders that generate routine digoxin levels on a fixed schedule—regardless of patient status—review those orders now. A standing order without individualized clinical justification is a liability under any therapeutic drug assay coverage policy.
Coverage Indications at a Glance
The policy data for this modification does not include a granular, indication-level breakdown. The table below reflects what CMS generally applies to therapeutic drug assay coverage policies for digoxin monitoring.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Active digoxin therapy with clinical indication for monitoring | Covered | See Affected Codes section | Medical necessity documentation required in chart |
| Suspected digoxin toxicity | Covered | See Affected Codes section | Acute clinical presentation should be documented |
| Dose adjustment monitoring | Covered | See Affected Codes section | Document clinical rationale for each test |
| Routine/scheduled testing without individualized justification | Not Covered | N/A | Standing orders without clinical basis will not meet medical necessity |
| Testing in patients not currently prescribed digoxin | Not Covered | N/A | No active prescription = no coverage basis |
| Preventive or screening use | Not Covered | N/A | Digoxin assay is not a screening test under CMS policy |
Treat this table as a starting framework, not a final word. The actual modified policy may include more specific criteria. Once CMS publishes the full updated language, map your indication documentation against each row.
CMS Digoxin Therapeutic Drug Assay Billing Guidelines and Action Items 2026
Here's what your team needs to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's LCD on therapeutic drug monitoring now. Your Medicare Administrative Contractor may have a local coverage determination that modifies or supplements the national CMS coverage policy for digoxin assays. CMS national policy sets the floor—your MAC sets the ceiling. Call or check your MAC's website directly and document what you find. |
| 2 | Audit the last 90 days of digoxin assay claims. Run a report on all digoxin therapeutic drug assay claims submitted in the past 90 days. Look for patterns: Are assays ordered on a fixed schedule? Are chart notes documenting clinical rationale at the individual-encounter level? Any claim where the documentation doesn't answer "why today?" is a potential denial under the updated coverage policy. |
| 3 | Update your prior authorization workflows. Even if digoxin assays don't require prior authorization at the national CMS level, some Medicare Advantage plans and supplemental policies do require it. Verify your payer mix and update your intake process before the effective date of May 15, 2026. A missed prior auth requirement is an avoidable write-off. |
| 4 | Brief your ordering providers on documentation standards. This is where reimbursement actually gets protected or lost. Your providers need to document the specific clinical reason for each digoxin assay at the time of ordering. "Per protocol" or "routine monitoring" won't hold up. Train your clinical staff to write active, individualized justifications—something like "patient on digoxin 0.125mg daily, recent change in renal function, assay ordered to assess potential toxicity risk." |
| 5 | Update your charge capture workflow to flag digoxin assay claims for documentation review. Build a hard stop or a pre-submission review flag into your billing software for digoxin therapeutic drug assay claims. A billing team member should confirm documentation is present before claims go out the door—especially after May 15, 2026, when the modified policy is in effect. |
| 6 | Watch for updated policy language on the CMS website. The full text of this modification isn't fully available yet. Bookmark the CMS policy page and check back as May 15 approaches. If you're not sure how the updated criteria apply to your patient mix, talk to your compliance officer before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Digoxin Therapeutic Drug Assay Under This Policy
The policy data provided for this modification does not list specific CPT, HCPCS, or ICD-10 codes. Do not assume your current codes are unaffected—wait for the full policy text and verify against your charge master.
Common Codes Used in Digoxin Therapeutic Drug Assay Billing (For Reference)
The policy data does not confirm these codes are explicitly listed in the modified CMS policy. These are widely used in digoxin monitoring billing and are included here for reference only. Confirm against the actual policy document before using them as compliance guidance.
| Code | Type | Description |
|---|---|---|
| Not specified in policy data | — | The CMS modification does not list specific codes in available data |
Once CMS publishes the full updated policy text, map every code your team uses for digoxin monitoring against the confirmed list. If a code you're currently using doesn't appear, escalate to your billing consultant or compliance officer before submitting claims under the modified policy.
The absence of code data in a policy modification is itself a signal. It usually means the change is criteria-based—a shift in medical necessity standards, documentation requirements, or frequency limits—rather than a code addition or deletion. That's actually the harder kind of change to manage, because it doesn't show up in a charge capture audit. It shows up in your denial rate.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.